NCT02930967 - Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2019

Conditions

Recurrent PD-L1+ Malignant TumorsMetastatic PD-L1+ Malignant Tumors

Interventions

BIOLOGICAL

autologous CSR T

Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).

Trial Locations (1)

100028

RECRUITING

China Meitan General Hospital, Beijing